A Study to Compare SB16 (Proposed Denosumab Biosimilar) to Prolia® in Postmenopausal Women With Osteoporosis

Postmenopausal Osteoporosis Clinical Trial

Official title:

A Phase III, Randomised, Double-blind, Multicentre Clinical Study to Compare the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Between SB16 (Proposed Denosumab Biosimilar) and Prolia® in Postmenopausal Women With Osteoporosis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04664959
• Other study ID #: SB16-3001
• Status: Completed
• Phase: Phase 3
• Start date: November 26, 2020
• Est. completion date: December 19, 2022

Study information

• Verified date: December 2022
• Source: Samsung Bioepis Co., Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a randomised, double-blind, multicentre study to evaluate the efficacy, safety, PK, PD, and immunogenicity of SB16 compared to Prolia® in postmenopausal women with osteoporosis.

Description:

Subjects will be randomised in a 1:1 ratio to receive either SB16 or Prolia®. At Month 12, subjects in Prolia® treatment group will be randomised again in a 1:1 ratio to either continue on Prolia® treatment or be transitioned to SB16 treatment. Investigational product (60 mg in 1 mL of SB16 or Prolia®) will be given subcutaneously every 6 months up to Month 12, and the last assessment will be done at Month 18.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 457
• Est. completion date: December 19, 2022
• Est. primary completion date: June 20, 2022
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 55 Years to 80 Years

Eligibility

Inclusion Criteria:

• Postmenopausal women who are 55 to 80 years of age at Screening

• Ambulatory and visually unimpaired to participate in the study at Screening, in the opinion of the Investigator

• Absolute BMD consistent with T-score at the total hip or lumbar spine of -4 and -2.5 at Screening

• At least three evaluable vertebrae within L1 to L4, one evaluable femoral neck, and one evaluable hip joint for BMD measurement at Screening

• Biologic naïve at Screening

• Body weight of 50 kg and 90 kg at Screening

Exclusion Criteria:

• One severe or more than two moderate vertebral fractures on spinal X-ray according to Genant classification at Screening

• History of hip fracture or bilateral hip replacement at Screening

• Uncorrected vitamin D deficiency at Screening

• Hypercalcemia or hypocalcaemia at Screening

• Inadequate haematological function at Screening

• Inadequate renal or hepatic function at Screening

• Known allergic reactions, hypersensitivity, or intolerance to denosumab or to any ingredients of the IP, including latex allergy or hereditary problems of fructose intolerance at Screening

• May not tolerate long-term calcium or vitamin D supplementation or subject with malabsorption of calcium or vitamin D supplements, in the opinion of the Investigator, at Screening

• Use of any of the medications that can affect BMD

• Use of any non-biologic IP that is not indicated for osteoporosis from another study or use of an investigational device at Screening

• Non-osteoporosis medical conditions that can affect BMD at Screening

• Any clinically significant disease or disorder or laboratory abnormality which, in the opinion of the Investigator, would prevent the subject from completing the study or the interpretation of the study results at Screening and Randomisation

Related Conditions & MeSH terms

• Osteoporosis
• Osteoporosis, Postmenopausal
• Postmenopausal Osteoporosis

Intervention

Drug:
• SB16 (Proposed Denosumab Biosimilar)
Subjects randomised into SB16 group will receive SB16 (60 mg in 1 mL) subcutaneously every 6 months. At Month 12, subjects transited from Prolia® group to SB16 group will receive SB16 (60 mg in 1 mL) subcutaneously.
• Prolia® (Denosumab)
Subjects randomised into Prolia® group will receive Prolia® (60 mg in 1 mL) subcutaneously every 6 months.

Locations

Country	Name	City	State
Poland	SB Investigative Site	Kraków
Poland	SB Investigative Site	Lódz
Poland	SB Investigative Site	Siedlce
Poland	SB Investigative Site	Warszawa
Poland	SB Investigative Site	Zamosc

Sponsors (1)

Lead Sponsor	Collaborator
Samsung Bioepis Co., Ltd.

Country where clinical trial is conducted

Poland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percent change from baseline in lumbar spine BMD at Month 12		Baseline and Month 12